News Column

Study Results from Sichuan University Provide New Insights into Cancer Gene Therapy

June 16, 2014

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting out of Chengdu, People's Republic of China, by NewsRx editors, research stated, "LKB1 and FUS1 are two kinds of new tumor suppressor genes as well as early-stage genes in lung cancer. Recent studies showed that LKB1 and FUS1 play important roles in lung carcinogenesis process."

Our news journalists obtained a quote from the research from Sichuan University, "We hypothesized that combined gene therapy with LKB1 and FUS1 could inhibit lung cancer growth and development synergistically. In this study, two kinds of tumor suppressor genes, LKB1 and FUS1, were constructed in an eukaryotic coexpression plasmid pVITRO(2), and then, we evaluated the synergistic effects of the two genes on anticancer activity and explored the relevant molecular mechanisms. We defined coexpression of LKB1 and FUS1 could synergistically inhibited lung cancer cells growth, invasion and migration and induced the cell apoptosis and arrested cell cycle in vitro. Intratumoral administration of liposomes: pVITRO(2)-LKB1-FUS1 complex (LPs-pVITRO(2)-LKB1-FUS1) into subcutaneous lung tumor xenograft resulted in more significant inhibition of tumor growth. Furthermore, intravenous injection of LPs-pVITRO(2)-LKB1-FUS1 into mice bearing experimental A549 lung metastasis demonstrated synergistic decrease in the number of metastatic tumor nodules. Finally, combined treatment with LKB1 and FUS1 prolonged overall survival in lung tumor-bearing mice. Further study showed that the synergistic anti-lung cancer effects of coexpression of LKB1 and FUS1 might be related to upregulation of p-p53, p-AMPK and downregulation of p-mTOR, p-FAK, MMPs, NEDD9, VEGF/R and PDGF/R."

According to the news editors, the research concluded: "Our results suggest that combined therapy with eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes may be a novel and efficient treatment strategy for human lung cancer."

For more information on this research see: Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 2014;140(6):895-907. Journal of Cancer Research and Clinical Oncology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer -; Journal of Cancer Research and Clinical Oncology -

Our news journalists report that additional information may be obtained by contacting L.D. Li, Sichuan University, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, People's Republic of China. Additional authors for this research include C.J. Yu, J. Ren, S.J. Ye, W.J. Ou, Y. Wang, W.H. Yang, G.X. Zhong, X. Chen, H.S. Shi, X.L. Su, L.J. Chen and W. Zhu (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Chengdu, Genetics, Oncology, Lung Cancer, Bioengineering, Lung Neoplasms, Cancer Gene Therapy, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cancer Gene Therapy Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters